Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects
- Conditions
- Healthy
- Interventions
- Drug: BIIB033Drug: Placebo
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 72
- Registration Number
- NCT01052506
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Biological: BIIB019 (Daclizumab)Biological: trivalent seasonal influenza vaccine
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 410
- Registration Number
- NCT01051349
- Locations
- 🇬🇧
Research Site, Stoke-on-Trent, United Kingdom
BIIB014 Cardiovascular Monitoring Study
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: BIIB014 50mgDrug: BIIB014 100mg
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 24
- Registration Number
- NCT01035515
- Locations
- 🇺🇸
Quintiles Inc, Overland Park, Kansas, United States
BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam
- Conditions
- Healthy
- Interventions
- Drug: BIIB014Drug: Placebo
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 28
- Registration Number
- NCT01017666
- Locations
- 🇬🇧
InCROM Clinical Research Unit, London, United Kingdom
Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: BIIB021 and FoodDrug: BIIB0121 and Antacid
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT01017198
- Locations
- 🇺🇸
Reseach Facility, San Antonio, Texas, United States
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 54
- Registration Number
- NCT01004081
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: BIIB022 With Paclitaxel and Carboplatin
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 18
- Registration Number
- NCT00970580
- Locations
- 🇺🇸
Resesarch Site, Denver, Colorado, United States
Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects
- Conditions
- Pain, NeuropathicNeuropathic Pain
- Interventions
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 16
- Registration Number
- NCT00964288
Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants
- Conditions
- Sciatica
- Interventions
- Drug: BG00010 (Neublastin)Drug: Placebo
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 48
- Registration Number
- NCT00961766
- Locations
- 🇦🇺
Research Site, Adelaide, South Australia, Australia
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 40
- Registration Number
- NCT00956436
- Locations
- 🇬🇧
Resesarch Site, Edgbaston, Birmingham, United Kingdom